Telix Pharmaceuticals Limited (TLX) News
Track canonical SquawkNews coverage tagged to TLX, Telix Pharmaceuticals Limited. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 50 indexed stories across 20 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Telix Pharmaceuticals Announces FDA Fast Track For BiPASS Pre Biopsy Prostate Imaging
Telix Pharmaceuticals Limited ASX:TLX
REGULATION | Sep 30, 2026, 01:37 AM UTC
L
Telix (TLX) Gets FDA Fast Track for BiPASS Imaging
Telix was granted FDA Fast Track designation for its BiPASS pre—biopsy prostate cancer imaging.Material DetailsContext by AI AnalystThis is an early regulatory acceleration step that could speed development of Telix’s im
REGULATION | Sep 30, 2026, 12:27 AM UTC
L
Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging
Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging
REGULATION | Sep 30, 2026, 12:27 AM UTC
L
Telix Pharmaceuticals Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 02:40 PM UTC
L
HC Wainwright & Co. reiterates Buy rating on Telix Pharmaceuticals, $20 price target
HC Wainwright & Co. reiterated their Buy rating on Telix Pharmaceuticals's stock with a price target of $20.00.The price target implies an upside of 25.8% from the Sep 25 close of $15.90.Key takeaways from the analyst no
MNA | Sep 25, 2026, 02:29 PM UTC
L
Telix Pharmaceuticals Price Target Maintained With a $22.00/Share by Wedbush
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 12:25 PM UTC
L
Wedbush reiterates Outperform rating on Telix Pharmaceuticals, $22 price target
Wedbush reiterated their Outperform rating on Telix Pharmaceuticals's stock with a price target of $22.00.The price target implies an upside of 36.8% from the Sep 23 close of $16.08.Key takeaways from the analyst noteStr
MNA | Sep 23, 2026, 12:15 PM UTC
H
Crude Oil Down 4%; Intel Shares Move Higher
U.S. stocks traded higher midway through trading, with the S&P 500 gaining over 1% on Monday. The Dow traded up 0.45% to 51,917.33 while the NASDAQ climbed 1.77% to 26,992.96. The S&P 500 also rose, gaining, 1.16% to 7,7
LIVE | Sep 21, 2026, 04:04 PM UTC
M
Sazerac launches €5.55 takeover offer for Berentzen
Sazerac launched a takeover offer for all shares of Berentzen at €5.55 ($6.37) apiece, supported by Berentzen’s supervisory and executive boards. Bids, mergers, acquisitions and disposals were reported by 0930 GMT on Mon
MNA | Sep 21, 2026, 11:37 AM UTC
H
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Shares of Lobo Technologies Ltd (NASDAQ: LOBO ) rose sharply in pre-market trading after the company reported a year-over-year increase in H1 financial results. Lobo EV Technologies posted a H1 loss of 7 cents per share,
LIVE | Sep 21, 2026, 09:01 AM UTC
H
Telix to Acquire ITM Isotope Technologies in Up to $2.35B Deal
Telix Pharmaceuticals signed an agreement to acquire privately held ITM Isotope Technologies Munich SE for a transaction valued at up to US$2.35 billion, to strengthen its position in radiopharmaceutical and radioisotope
EQUITY | Sep 21, 2026, 01:53 AM UTC
H
Telix to acquire ITM for $1.65B upfront plus up to $700M
Telix Pharmaceuticals said it will acquire 100% of ITM for $1.65B upfront and up to $700M in milestone payments tied to ITM-11 approvals and sales, subject to approvals. Closing is expected by end FY 2026.
EQUITY | Sep 21, 2026, 01:02 AM UTC
L
TLX - Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
TLX - Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
NEWS | Sep 21, 2026, 12:55 AM UTC
M
Telix expects 2026 combined pro forma revenue above $1.3B
EARNINGS | Sep 20, 2026, 11:28 PM UTC
M
Telix to assume $302 million of debt at completion
Telix said it will assume $302 million of debt at completion.
MNA | Sep 20, 2026, 11:25 PM UTC
M
Telix to issue 105.8 million shares at $11.84 each
EQUITY | Sep 20, 2026, 11:24 PM UTC
M
Telix upfront payment includes $1.25B in newly issued shares
Wire reports Telix upfront payment includes $1.25B of newly issued shares.
EQUITY | Sep 20, 2026, 11:24 PM UTC
M
Telix to pay initial $1.65B for privately held ITM
Telix plans to pay an initial $1.65B for privately held ITM.
MNA | Sep 20, 2026, 11:21 PM UTC
H
Telix Pharmaceuticals agrees to acquire ITM Isotope for about $1.65B
Telix Pharmaceuticals (ASX:TLX) agreed to acquire Germany-based ITM Isotope Technologies Munich SE for about $1.65 billion on a cash- and debt-free basis. After adjustments, ITM shareholders are expected to receive about
EQUITY | Sep 20, 2026, 11:20 PM UTC
M
RWE buys more in M31, raising Amprion stake to ~58%
RWE said it bought an additional 3% stake in M31, which holds about three-quarters of shares in transmission system operator Amprion. RWE’s pro-rata Amprion stake will rise to about 58%, making it the majority.
MNA | Sep 16, 2026, 05:14 PM UTC
M
Biotech shares hit 52-week highs; MNOV, RVTY, TLX jump
Several biotech stocks reached 52-week highs on Sept. 15, 2026, including MediciNova (MNOV), Revvity (RVTY), and Telix (TLX), with the report attributing strength to gains on certain clinical or financial results.
EQUITY | Sep 16, 2026, 05:36 AM UTC
L
Telix climbs for second trading day following Pixclara approval
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser
NEWS | Sep 15, 2026, 04:01 PM UTC
L
TLX: Strong imaging sales, new FDA approvals, and global trial progress drive growth
A vertically integrated radiopharma company reported strong imaging sales and expanded its global infrastructure. Recent FDA approval of Pixclara opens a new market in glioma imaging, while the BiPASS and ProstACT GLOBAL
REGULATION | Sep 15, 2026, 03:38 PM UTC
L
TLX: Strong imaging sales, FDA approvals, and late-stage trials drive growth and innovation
The company highlighted strong commercial performance in imaging, recent FDA approvals, and a robust late-stage pipeline in urology and neuro-oncology. Key trials like BiPASS and ProstACT GLOBAL 2 are progressing, with m
EARNINGS | Sep 15, 2026, 03:20 PM UTC
L
Telix Pharmaceuticals Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 02:06 PM UTC
H
Radiant Logistics, Waystar, Forgent Power Solutions And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling around 300 points on Tuesday. Shares of Radiant Logistics Inc (NYSE: RLGT ) rose sharply after the company reported better-than-expected fourth-quarter financial r
LIVE | Sep 15, 2026, 01:53 PM UTC
L
Telix Pharmaceuticals Raised to Buy From Hold by Bell Potter >TLX.AU
Telix Pharmaceuticals Raised to Buy From Hold by Bell Potter >TLX.AU
NEWS | Sep 15, 2026, 01:22 AM UTC
L
Telix Pharmaceuticals Target Price Raised 2.4% to A$30.00/Share by Jefferies>TLX.AU
Telix Pharmaceuticals Target Price Raised 2.4% to A$30.00/Share by Jefferies>TLX.AU
NEWS | Sep 14, 2026, 10:34 PM UTC
H
Telix ADRs rise after FDA approves Pixclara brain imaging
Telix Pharmaceuticals Limited ADRs gained after the FDA approved its new drug application for Pixclara, used in brain cancer imaging; ADRs rose 7.9% to $12.18 in premarket.
REGULATION | Sep 14, 2026, 01:03 PM UTC
L
FDA approves Telix brain cancer imaging drug Pixclara
The Food and Drug Administration approved Telix Pharmaceuticals’ NASDAQ:TLX Pixclara, a radioactive imaging drug used to help evaluate patients with glioma, the company said Sunday.Pixclara, also known as floretyrosine F
REGULATION | Sep 14, 2026, 12:41 AM UTC
L
FDA Approves Telix's Brain Cancer Imaging Drug Pixclara
MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 // -- Telix Pharmaceuticals Limited (ASX:TLX, NASDAQ:TLX, "Telix") today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its N
REGULATION | Sep 13, 2026, 10:57 PM UTC
L
Telix Pharmaceuticals Says FDA Approves Telix Brain Cancer Imaging Drug Pixclara
Telix Pharmaceuticals Limited ASX:TLX
REGULATION | Sep 13, 2026, 10:31 PM UTC
L
Telix to present at Morgan Stanley and H.C. Wainwright healthcare conferences
Telix Pharmaceuticals Limited says Dr. Christian Behrenbruch and Kevin Richardson, CEO Precision Medicine, will present at the Morgan Stanley 24th Annual Global Healthcare Conference and the H.C. Wainwright 28th Annual G
EQUITY | Sep 09, 2026, 10:32 AM UTC
L
Telix to present at two healthcare investor conferences
Telix (TLX) plans presentations at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 09, 2026, 10:30 AM UTC
M
TLX shares rise about 5% ahead of FDA decision next Friday
NASDAQ-listed Telix Pharmaceuticals (TLX) climbed for the week as investors focused on a U.S. FDA decision due next Friday on its brain-cancer imaging agent. TLX traded around $11.90 on Friday.
REGULATION | Sep 04, 2026, 06:43 PM UTC
L
Goldman adds three European “Conviction List” picks: RWE, Adyen, TLX
Goldman Sachs added an energy multinational, a Dutch payments processor and a German insurer to its latest European “Conviction List — Directors' Cut” for September, highlighting buy-rated picks.
EQUITY | Sep 02, 2026, 12:06 PM UTC
L
HC Wainwright maintains Telix price target at $20.00
HC Wainwright & Co. maintained its price target for Telix Pharmaceuticals at $20.00 per share, according to Benzinga.
EQUITY | Sep 02, 2026, 11:45 AM UTC
L
6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More
BEIJING (dpa-AFX) - Today's after-hours gainers in the healthcare sector included Universe Pharmaceuticals, which drew attention after disclosing multiple Schedule 13G filings; bioAffinity Technologies, which is explorin
EQUITY | Sep 02, 2026, 02:56 AM UTC
M
Telix completes patient enrollment in Phase 3 BiPASS study
Telix Pharmaceuticals Limited announced completion of patient enrollment in its Phase 3 BiPASS study for commercial PSMA-PET1 imaging agents, Illuccix.
REGULATION | Sep 01, 2026, 10:27 PM UTC
M
TLX completes enrollment in Phase 3 BiPASS study
TLX says it has completed enrollment in its Phase 3 BiPASS study and aligned with the FDA on the NDA pathway.
REGULATION | Sep 01, 2026, 10:18 PM UTC
L
Mark Nelson to continue on Telix board as non-executive director
Mark Nelson will continue to serve on Telix’s board as a non-executive director after serving as interim chair.
EQUITY | Aug 31, 2026, 10:23 PM UTC
L
Telix appoints David Gill as chair
Telix has appointed David Gill as chair.
EQUITY | Aug 31, 2026, 10:23 PM UTC
L
TLX appoints David Gill as chair
Telix appoints David Gill as chair of the company, according to TradeXchange Newsdesk.
EQUITY | Aug 31, 2026, 10:21 PM UTC
L
Telix Pharmaceuticals guides FY 2026 revenue $950M–$970M and R&D $230M–$270M
Telix Pharmaceuticals guides FY 2026 revenue to $950M–$970M and expects total income above $1B, while reaffirming R&D expenditure of $230M–$270M, supported by other income from Regeneron.
EARNINGS | Aug 20, 2026, 06:08 AM UTC
L
TLX - Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
TLX - Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
EQUITY | Aug 20, 2026, 12:32 AM UTC
L
TLX - Telix H1 2026 Results: Investor Webcast Notification
TLX - Telix H1 2026 Results: Investor Webcast Notification
EQUITY | Jul 30, 2026, 10:37 PM UTC
H
Reported Earlier, Telix FY2026 Revenue Guidance $950M-$970M Plus $40M Regeneron Payment, Total Expected Above $1B
Reported Earlier, Telix FY2026 Revenue Guidance $950M-$970M Plus $40M Regeneron Payment, Total Expected Above $1B
EARNINGS | Jul 21, 2026, 06:43 AM UTC
H
Telix Pharmaceuticals price target lowered to $22 from $22.50 at Citi
Citi lowered the firm's price target on Telix Pharmaceuticals to $22 from $22.50 and keeps a Buy rating on the shares. Q2 Visible Alpha consensus of $184M in Illuccix/Gozellix sales "looks reasonable," says the analyst,
EQUITY | Jul 07, 2026, 04:51 PM UTC
L
Reported Earlier, Telix Achieves FDA Alignment On Clinical Protocol And Statistical Framework Across Three Standard Of Care Combination Coho
Reported Earlier, Telix Achieves FDA Alignment On Clinical Protocol And Statistical Framework Across Three Standard Of Care Combination Cohorts
REGULATION | Jul 02, 2026, 06:53 AM UTC
L
TLX Updates Neuro-Oncology
Telix hosts educational webinar on neuro-oncology portfolio update and future therapeutic directions
EQUITY | Jun 22, 2026, 09:40 PM UTC